| Download the amazing global Makindo app: ✅ Means NICE/National Guidelines 2026 compliant Android | Apple | |
|---|---|
| MEDICAL DISCLAIMER: Educational use only. Not for diagnosis or management. See below for full disclaimer. |
Co-careldopa — FY prescribing ⚠️ 💊
Do not stop Parkinson medication abruptly
- NICE NG71 requires inpatient antiparkinsonian medicines at appropriate individual times; missed or poorly absorbed doses may cause acute akinesia or a neuroleptic-malignant-like syndrome.
- If nil by mouth or swallowing is unsafe, obtain urgent specialist/pharmacy advice for route alternatives rather than omitting doses; avoid routine dopamine-blocking antiemetics/antipsychotics.
- Record the patient-specific administration times and ask the ward team to prioritise them.
UK sources (checked 4 Nov 2026): NICE NG71: Parkinson disease and inpatient medicines
Clinical safety: educational editorial draft, not an authorised NHS prescribing order. Clinical/pharmacy sign-off pending. Check local policies, BNF/BNFC, up-to-date guidance and individual patient factors before any treatment.
Co-careldopa — FY prescribing ⚠️ 💊
⚠️ Editorial teaching card; not a prescribing instruction. Confirm current BNF/BNFC, SmPC, local formulary and specialist advice for any dose, route or formulation. Independent pharmacist sign-off pending.
🧬 Pharmacology and role
Levodopa/carbidopa replenishes brain dopamine in Parkinson disease while reducing peripheral levodopa conversion.
🔎 Before giving
- Record the patient-specific times in the medication chart, not just a generic morning/lunch/evening schedule.
- If nil by mouth, dysphagic or vomiting, obtain urgent Parkinson specialist/pharmacy advice for alternative route/formulation.
- Observe mobility, swallowing, postural BP, hallucinations and dyskinesia.
🚨 Avoidable error / escalation
Do not abruptly omit time-critical Parkinson medicines: acute akinesia and neuroleptic-malignant-like syndromes may result.
UK references: NICE NG71 Parkinson disease · Parkinsons UK hospital medicines
Educational draft 4 November 2026; individual regimen and dose NOT clinically signed off.
| The content on this website is provided for educational and informational purposes only to support exam preparation (e.g., MLA, MRCP, USMLE) and learning. This is NOT medical advice, diagnosis, treatment, or professional guidance. It does not replace consultation with a qualified healthcare professional, official guidelines (e.g., NICE, GMC, BNF), or supervised clinical practice. Always verify information with current, authoritative sources. Makindo and its contributors accept no liability for any reliance on this content, including errors, omissions, or any resulting harm, loss, or consequences. By using this site, you agree to these terms. |
|
|
Categories
- Acute Medicine
- Anaesthetics and Critical Care
- Cardiology
- Collections
- Dermatology
- Differentials
- Drugs
- Electrocardiogram
- Emergency Medicine
- Endocrinology
- ENT
- Foundation Doctors
- Gastroenterology
- General Practice
- Genetics
- Geriatric Medicine
- Gynaecology
- Haematology
- Hepatology
- Immunology
- Infectious Diseases
- Investigations
- Mental Health
- Microbiology
- Nephrology
- Neurology
- Neurosurgery
- Obstetrics
- Oncology
- Ophthalmology
- Oral Medicine and Dentistry
- OSCE
- Paediatrics
- Palliative
- Pharmacology
- Physiology
- Procedures
- Psychiatry
- Public Health
- Radiology
- Respiratory
- Resuscitation
- Revision Topics
- Rheumatology
- Stroke
- Surgery
- Toxicology
- Trauma and Orthopaedics
- Urology
- Vascular Surgery